Abstract
Glioblastoma is the most common and deadly type of brain cancer. The poor prognosis may be largely attributed to inadequate disease response to current chemotherapeutic agents. Activation of p38 is associated with deleterious outcomes in glioblastoma patients, as its signaling mediates chemoresistance mechanisms. Antimicrobial peptide tilapia piscidin (TP) 4 was identified from Nile tilapia (Oreochromis niloticus) and exhibits strong bactericidal effects on Gram-positive and Gram-negative bacteria. TP4 also has anticancer activity toward human triple-negative breast cancer cells and glioblastoma cells. In the present study, we tested the cytotoxic effects of combined TP4 and p38 inhibitors on glioblastoma U251 cells. We found that the combination of TP4 and p38 inhibitors (SB202190 and VX-745) enhanced cytotoxicity in U251 glioblastoma cells but not noncancerous neural cells. Cytotoxicity from the combination treatments proceeded via necrosis and not apoptosis. Mechanistically, SB202190 potentiated TP4-induced mitochondrial dysfunction, reactive oxygen species generation and unbalanced antioxidant status, which resulted in necrotic cell death. Thus, we demonstrated for the first time that combinations of TP4 and p38 inhibitors have the potential to preferentially target glioblastoma cells, while sparing noncancerous neural cells.
Similar content being viewed by others
Abbreviations
- TP4:
-
Tilapia piscidin 4
- TMZ:
-
Temozolomide
- BCNU:
-
Bis-chloroethylnitrosourea
- Nrf2:
-
Nuclear factor erythroid 2-related factor 2
- VEGF:
-
Vascular endothelial growth factor
- DHE:
-
Dihydroethidium
- PI:
-
Propidium iodide
- TMRE:
-
Tetramethylrhodamine, ethyl ester
- DCF-DA:
-
2′,7′-Dichlorodihydrofluorescein diacetate
- NAC:
-
N-Acetyl-l-cysteine
- UCP:
-
Uncoupling protein
- SOD:
-
Superoxide dismutase
- DMEM:
-
Dulbecco’s modified Eagle’s medium
- RIP3:
-
Receptor-interacting protein kinase 3
References
Davis ME (2016) Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 20(5):S2–8. https://doi.org/10.1188/16.CJON.S1.2-8
Nizamutdinov D, Stock EM, Dandashi JA, Vasquez EA, Mao Y, Dayawansa S, Zhang J, Wu E, Fonkem E, Huang JH (2018) Prognostication of survival outcomes in patients diagnosed with glioblastoma. World Neurosurg 109:e67–e74. https://doi.org/10.1016/j.wneu.2017.09.104
Ma L, Liu J, Zhang X, Qi J, Yu W, Gu Y (2015) p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ. Med Oncol 32(3):69. https://doi.org/10.1007/s12032-015-0517-y
Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G (2010) BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer 10:30. https://doi.org/10.1186/1471-2407-10-30
Demuth T, Reavie LB, Rennert JL, Nakada M, Nakada S, Hoelzinger DB, Beaudry CE, Henrichs AN, Anderson EM, Berens ME (2007) MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther 6(4):1212–1222. https://doi.org/10.1158/1535-7163.MCT-06-0711
Yoshino Y, Aoyagi M, Tamaki M, Duan L, Morimoto T, Ohno K (2006) Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. Int J Oncol 29(4):981–987
Munoz L, Yeung YT, Grewal T (2016) Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells. Cancer Biol Ther 17(4):355–363. https://doi.org/10.1080/15384047.2016.1139249
Duffy JP, Harrington EM, Salituro FG, Cochran JE, Green J, Gao H, Bemis GW, Evindar G, Galullo VP, Ford PJ, Germann UA, Wilson KP, Bellon SF, Chen G, Taslimi P, Jones P, Huang C, Pazhanisamy S, Wang YM, Murcko MA, Su MS (2011) The discovery of VX-745: a Novel and selective p38alpha kinase inhibitor. ACS Med Chem Lett 2(10):758–763. https://doi.org/10.1021/ml2001455
Melloni C, Sprecher DL, Sarov-Blat L, Patel MR, Heitner JF, Hamm CW, Aylward P, Tanguay JF, DeWinter RJ, Marber MS, Lerman A, Hasselblad V, Granger CB, Newby LK (2012) The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am Heart J 164(5):646–653. https://doi.org/10.1016/j.ahj.2012.07.030
Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP (2016) A First-in-human phase i study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer. Clin Cancer Res 22(5):1095–1102. https://doi.org/10.1158/1078-0432.CCR-15-1718
Pan CY, Tsai TY, Su BC, Hui CF, Chen JY (2017) Study of the antimicrobial activity of tilapia piscidin 3 (TP3) and TP4 and their effects on immune functions in hybrid tilapia (Oreochromis spp.). PLoS ONE 12(1):e0169678. https://doi.org/10.1371/journal.pone.0169678
Ting CH, Chen JY (2018) Nile Tilapia derived TP4 shows broad cytotoxicity toward to non-small-cell lung cancer cells. Mar Drugs. https://doi.org/10.3390/md16120506
Ting CH, Chen YC, Wu CJ, Chen JY (2016) Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer. Oncotarget 7(26):40329–40347. https://doi.org/10.18632/oncotarget.9612
Su BC, Pan CY, Chen JY (2019) Antimicrobial peptide TP4 induces ROS-mediated necrosis by triggering mitochondrial dysfunction in wild-type and mutant p53 glioblastoma cells. Cancers (Basel). https://doi.org/10.3390/cancers11020171
Cho KJ, Seo JM, Kim JH (2011) Bioactive lipoxygenase metabolites stimulation of NADPH oxidases and reactive oxygen species. Mol Cells 32(1):1–5. https://doi.org/10.1007/s10059-011-1021-7
Dan Dunn J, Alvarez LA, Zhang X, Soldati T (2015) Reactive oxygen species and mitochondria: a nexus of cellular homeostasis. Redox Biol 6:472–485. https://doi.org/10.1016/j.redox.2015.09.005
Mittler R (2017) ROS are good. Trends Plant Sci 22(1):11–19. https://doi.org/10.1016/j.tplants.2016.08.002
D’Arcy MS (2019) Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int 43(6):582–592. https://doi.org/10.1002/cbin.11137
Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N (2013) Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta 1833(12):3448–3459. https://doi.org/10.1016/j.bbamcr.2013.06.001
Gu WJ, Liu HL (2013) Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA. Anticancer Drugs 24(6):566–576. https://doi.org/10.1097/CAD.0b013e3283608bc5
Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256(1):42–49. https://doi.org/10.1006/excr.2000.4838
Fernald K, Kurokawa M (2013) Evading apoptosis in cancer. Trends Cell Biol 23(12):620–633. https://doi.org/10.1016/j.tcb.2013.07.006
Trejo-Solis C, Serrano-Garcia N, Escamilla-Ramirez A, Castillo-Rodriguez RA, Jimenez-Farfan D, Palencia G, Calvillo M, Alvarez-Lemus MA, Flores-Najera A, Cruz-Salgado A, Sotelo J (2018) Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma. Int J Mol Sci. https://doi.org/10.3390/ijms19123773
Su Z, Yang Z, Xie L, DeWitt JP, Chen Y (2016) Cancer therapy in the necroptosis era. Cell Death Differ 23(5):748–756. https://doi.org/10.1038/cdd.2016.8
Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF 3rd, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27(7):659–666. https://doi.org/10.1038/nbt.1549
Masgras I, Carrera S, de Verdier PJ, Brennan P, Majid A, Makhtar W, Tulchinsky E, Jones GD, Roninson IB, Macip S (2012) Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. J Biol Chem 287(13):9845–9854. https://doi.org/10.1074/jbc.M111.250357
Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA (2011) Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques 50(2):98–115. https://doi.org/10.2144/000113610
Wang X, Ottosson A, Ji C, Feng X, Nordenskjold M, Henter JI, Fadeel B, Zheng C (2009) Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 94(4):470–478. https://doi.org/10.3324/haematol.13783
Johannessen TC, Bjerkvig R (2012) Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 12(5):635–642. https://doi.org/10.1586/era.12.37
Sangpairoj K, Vivithanaporn P, Apisawetakan S, Chongthammakun S, Sobhon P, Chaithirayanon K (2017) RUNX1 regulates migration, invasion, and angiogenesis via p38 MAPK pathway in human glioblastoma. Cell Mol Neurobiol 37(7):1243–1255. https://doi.org/10.1007/s10571-016-0456-y
Goldsmith CS, Kim SM, Karunarathna N, Neuendorff N, Gerard Toussaint L, Earnest DJ, Bell-Pedersen D (2018) Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness. BMC Cancer 18(1):43. https://doi.org/10.1186/s12885-017-3896-y
Sooman L, Lennartsson J, Gullbo J, Bergqvist M, Tsakonas G, Johansson F, Edqvist PH, Ponten F, Jaiswal A, Navani S, Alafuzoff I, Popova S, Blomquist E, Ekman S (2013) Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival. Med Oncol 30(3):638. https://doi.org/10.1007/s12032-013-0638-0
Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, Gilmour R, Graff JR, Jambrina E, Mader M, McCann D, Na S, Parsons SH, Pratt SE, Shih C, Stancato LF, Starling JJ, Tate C, Velasco JA, Wang Y, Ye XS (2014) Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther 13(2):364–374. https://doi.org/10.1158/1535-7163.MCT-13-0513
Weinberg SE, Chandel NS (2015) Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 11(1):9–15. https://doi.org/10.1038/nchembio.1712
Kishikawa JI, Inoue Y, Fujikawa M, Nishimura K, Nakanishi A, Tanabe T, Imamura H, Yokoyama K (2018) General anesthetics cause mitochondrial dysfunction and reduction of intracellular ATP levels. PLoS ONE 13(1):e0190213. https://doi.org/10.1371/journal.pone.0190213
Liou GY, Storz P (2010) Reactive oxygen species in cancer. Free Radic Res 44(5):479–496. https://doi.org/10.3109/10715761003667554
Gao Z, Sarsour EH, Kalen AL, Li L, Kumar MG, Goswami PC (2008) Late ROS accumulation and radiosensitivity in SOD1-overexpressing human glioma cells. Free Radic Biol Med 45(11):1501–1509. https://doi.org/10.1016/j.freeradbiomed.2008.08.009
Yoshii Y, Saito A, Zhao DW, Nose T (1999) Copper/zinc superoxide dismutase, nuclear DNA content, and progression in human gliomas. J Neurooncol 42(2):103–108
Smith PS, Zhao W, Spitz DR, Robbins ME (2007) Inhibiting catalase activity sensitizes 36B10 rat glioma cells to oxidative stress. Free Radic Biol Med 42(6):787–797. https://doi.org/10.1016/j.freeradbiomed.2006.11.032
Dalla Pozza E, Fiorini C, Dando I, Menegazzi M, Sgarbossa A, Costanzo C, Palmieri M, Donadelli M (2012) Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine. Biochim Biophys Acta 1823(10):1856–1863. https://doi.org/10.1016/j.bbamcr.2012.06.007
Alam JJ (2015) Selective brain-targeted antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves morris water maze performance in aged rats. J Alzheimers Dis 48(1):219–227. https://doi.org/10.3233/JAD-150277
Alam J, Blackburn K, Patrick D (2017) Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38alpha to reverse synaptic dysfunction in early Alzheimer’s disease. J Prev Alzheimers Dis 4(4):273–278. https://doi.org/10.14283/jpad.2017.41
Acknowledgements
This research was supported by intramural funding from the Marine Research Station (Jiaushi, Ilan), Institute of Cellular and Organismic Biology, Academia Sinica to Dr. Jyh-Yih Chen. We thank Dr. Pei-Jung Lu, National Cheng Kung University (Taiwan), for kindly providing the U251 human glioblastoma cell line.
Funding
This research was supported by intramural funding from the Marine Research Station (Jiaushi, Ilan), Institute of Cellular and Organismic Biology, Academia Sinica to Jyh-Yih Chen (Research Fellow).
Author information
Authors and Affiliations
Contributions
B-CS performed the experiments; B-CS analyzed the data; B-CS contributed reagents/materials/analysis tools; B-CS and J-YC wrote the paper.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Su, BC., Chen, JY. Pharmacological inhibition of p38 potentiates antimicrobial peptide TP4-induced cell death in glioblastoma cells. Mol Cell Biochem 464, 1–9 (2020). https://doi.org/10.1007/s11010-019-03643-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-019-03643-3